Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

Effect of 16 Weeks of Bosentan-Based Therapy on Cardiac MRI (cMRI) Derived Ventricular Function, 6-Minute Walk Test Distance (6MWD) and Borg Dyspnea Index (BDI) in Patients with Pulmonary Arterial Hyp

Himanshu Gupta

Myung Park


Srinivas Murali


S. G. Lloyd

Francisco Soto


Fernando Torres


N. Frey

Raymond Benza


Reviews

  Sign in to add a review

0 comments
Leave a Comment

Conference: 2010 International PHA Conference and Scientific Sessions

Release Date: 06.24.2010

Presentation Type: Abstracts

Gupta H1, Park MH2, Murali S3, Lloyd SG1, Soto FJ4, Torres F5, Frey N6, Benza RL3
1. University of Alabama at Birmingham, Birmingham, AL, USA 
2. University of Maryland School of Medicine, Baltimore, MD, USA 
3. Allegheny General Hospital, Pittsburgh, PA, USA 
4. Prevea Health, Green Bay, WI, USA 
5. University of Texas Southwestern Medical Center, Dallas, TX, USA 
6. Actelion Pharmaceuticals US, Inc., San Francisco, CA, USA

BACKGROUNDAdvances in cMRI technology have improved non-invasive assessment of right and left ventricular structure and function in PAH patients. COMPASS-3 is a prospective, multi-center study which assessed the utility of cMRI to evaluate prognosis in PAH. Changes in cMRI parameters after 16 weeks of bosentan therapy were investigated.

METHODS100 therapy-naïve PAH patients with baseline 6MWD 150-360m received bosentan for 16 wks. cMRI, 6MWD, and BDI were investigated at baseline and Wk 16.

RESULTSMean age was 55.5 yrs; time since diagnosis, 0.7±2.2 yrs, 59% had idiopathic PAH and 82% were female. By Wk 16 there were significant changes in several cMRI parameters (see Table). At 16 wks, mean±SD change in 6MWD was 22.2±75.8 m and BDI was -0.40±1.86.

CONCLUSIONSPreliminary results from the COMPASS-3 study show that bosentan monotherapy for 16 wks significantly improves right and left ventricular end-systolic volumes, ejection fraction and stroke volumes concurrent with improvement in functional parameters in PAH.

 

 

Total Cohort

Parameter

Delta Change (mean±SD, n)

P value 

LV End Dia Vol, ml

6.0±20.2, 86

0.0073

LV End Sys Vol, ml

-2.2±11.8, 86

0.0857

LV Ejection Fraction, %

4.0±10.0, 86

0.0004

LV Mass, g

2.1±13.6, 86

0.1592

RV End Dia Vol, ml

-2.1±36.2, 84

0.6017

RV End Sys Vol, ml

-8.6±29.0, 84

0.0081

RV Ejection Fraction, %

3.1±8.5, 84

0.0011

RV Mass, g

2.3±10.9, 83

0.0548

Stroke Vol, ml

7.3±18.8, 81

0.0008